Transaction overview
Fine Foods & Pharmaceuticals N.T.M., an Italian company listed on Euronext Star Milan, acquired 100% of Sofar from Alfasigma in a deal that closed on April 17, 2026. Fine Foods operates in the development and production of products for nutraceuticals, pharmaceuticals, and cosmetics sectors. The acquisition aims to strengthen Fine Foods' technological platforms by integrating complementary competencies and technologies.
Deal structure and financing
The specific financial details of the deal remain undisclosed. Fine Foods was advised on M&A matters by KPMG and PQE provided diligence support. Alfasigma worked with EY-Parthenon for their advisory needs, including due diligence on finance, operations, and IT aspects. No information is available regarding equity or debt financing, leverage metrics, seller-retained stakes, lock-up terms, or IPO optionality associated with this transaction.
Strategic context
Fine Foods sought to expand its technological platforms by acquiring Sofar, a company specializing in the development and production of pharmaceutical products and medical devices for various dosage forms. The acquisition provides Fine Foods with new competencies and technologies that complement their existing offerings, thereby enhancing product diversity and competitive positioning within the industry. Alfasigma's rationale for divesting Sofar includes focusing on core business areas while maintaining a strategic industrial collaboration agreement post-acquisition to continue producing portfolio products for Alfasigma.
Regulatory path
The acquisition was reviewed by relevant Italian regulatory bodies due to the deal’s domestic nature involving two Italian companies and the sector-specific regulations governing pharmaceutical production. No specific remedies were reported, but both HSR filings in Italy and EU notification procedures may have been considered given the potential impact on competition within the healthcare sector. The exact dates of these filings are not disclosed.
In summary, this acquisition marks a strategic move for Fine Foods to enhance its technological capabilities and expand product offerings through the integration of Sofar's specialized competencies.